ELEDON PHARMACEUTICALS INC (ELDN) Stock Price & Overview
NASDAQ:ELDN • US28617K1016
Current stock price
The current stock price of ELDN is 3.07 USD. Today ELDN is up by 2.33%. In the past month the price increased by 17.18%. In the past year, price increased by 8.48%.
ELDN Key Statistics
- Market Cap
- 243.267M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.52
- Dividend Yield
- N/A
ELDN Stock Performance
ELDN Stock Chart
ELDN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ELDN. When comparing the yearly performance of all stocks, ELDN is one of the better performing stocks in the market, outperforming 89.09% of all stocks.
ELDN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ELDN. ELDN has a great financial health rating, but its profitability evaluates not so good.
ELDN Earnings
ELDN Forecast & Estimates
13 analysts have analysed ELDN and the average price target is 8.16 USD. This implies a price increase of 165.8% is expected in the next year compared to the current price of 3.07.
ELDN Groups
Sector & Classification
ELDN Financial Highlights
Over the last trailing twelve months ELDN reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 50.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.99% | ||
| ROE | -33.35% | ||
| Debt/Equity | 0 |
ELDN Ownership
ELDN Latest News, Press Relases and Analysis
ELDN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ELDN
Company Profile
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Company Info
IPO: 2014-09-17
ELEDON PHARMACEUTICALS INC
19800 Macarthur Blvd., Suite 250
Irvine CALIFORNIA 92612 US
CEO: David-Alexandre C. Gros
Employees: 31
Phone: 19492388090
ELEDON PHARMACEUTICALS INC / ELDN FAQ
What does ELDN do?
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
What is the current price of ELDN stock?
The current stock price of ELDN is 3.07 USD. The price increased by 2.33% in the last trading session.
What is the dividend status of ELEDON PHARMACEUTICALS INC?
ELDN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ELDN stock?
ELDN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is ELDN stock listed?
ELDN stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for ELDN stock?
ELEDON PHARMACEUTICALS INC (ELDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.52).
Would investing in ELEDON PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ELDN.